IMMU Immunomedics, Inc.

+0  (3%)
Previous Close 6.42
Open 6.43
Price To book 0.00
Market Cap 703.30M
Shares 106,079,000
Volume 3,676,438
Short Ratio 4.12
Av. Daily Volume 3,822,690

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 to be initiated early 2017. BLA filing due mid-2017.
Cancer - metastatic triple-negative breast cancer
Phase 2 update provided at ASCO June 2016. Ongoing through 2017.
Non-small cell lung cancer (NSCLC)
Phase 2 interim data presented April 2016
Labetuzumab govitecan
Metastatic colorectal cancer (mCRC)
Phase 3 trial terminated due to poor efficacy
Clivatuzumab tetraxetan
Cancer - Pancreatic
Endpoints not met July 2015
Epratuzumab (EMBODY 1 and 2)

Latest News

  1. Billionaires' Best Healthcare Stock Picks of 2017 (So Far)
  2. 3 Companies That Need to Kick Their CEO to the Curb
  3. IMMUNOMEDICS INC Files SEC form 8-K/A, Submission of Matters to a Vote of Security Holders
  4. Biotech Premarket Movers: Arena, Immunomedics, Aralez
  5. Immunomedics Announces Publication of Results in Journal of Clinical Oncology, Demonstrating Treatment With Sacituzumab Govitecan (IMMU-132) Produces Early and Durable Responses in Patients With Metastatic Triple-Negative Breast Cancer
  6. Here’s What’s Moving Immunomedics, Inc. (IMMU) And Ocera Therapeutics Inc (OCRX)
  7. Judge Blocks $2B Immunomedics-Seattle Genetics Deal (IMMU,SGEN)
  8. Markets Rally Late to Close in the Green: Today's Research Reports on Immunomedics and VIVUS
  9. Why Immunomedics, Inc. Jumped Higher Today
  10. Why Marathon Oil, Signet Jewelers, and Immunomedics Jumped Today
  11. IMMUNOMEDICS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
  12. Immunomedics (IMMU) Stock Soars After Deal with Seattle Genetics Is Halted
  13. Judge puts Seattle Genetics' $2 billion deal with Immunomedics on hold
  14. Immunomedics Soars on Injunction Against Seattle Genetics Deal
  15. Are Options Traders Betting on a Big Move in Immunomedics (IMMU) Stock?
  16. Activist Investor Wins Control of Immunomedics Board Following Shareholder Vote
  17. Stockholders Endorse venBio’s Case for Meaningful Change at Immunomedics
  18. IMMUNOMEDICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  19. Immunomedics Board Institutes Measures As Stockholder Fiduciaries To Preserve Their Best Business Judgment To Protect The Rights Of All Stockholders
  20. venBio Encourages Stockholders to Vote for Change